Multidisciplinary Journal of Science and Technology

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH NUCLEOS(T)IDE ANALOGUES IN CHRONIC HEPATITIS B

Bakhtiyarova Dilnura Akbarovna

##semicolon## chronic hepatitis B, nucleos(t)ide analogues, antiviral therapy, safety, efficacy, HBV DNA

सार

Chronic hepatitis B (CHB) remains a major global public health problem, leading to progressive liver disease, cirrhosis, and hepatocellular carcinoma. Long-term antiviral therapy with nucleos(t)ide analogues (NAs) is the cornerstone of CHB management, aiming to suppress hepatitis B virus (HBV) replication, prevent disease progression, and reduce liver-related complications. Despite proven antiviral efficacy, prolonged NA therapy raises concerns regarding drug resistance, safety, renal and bone toxicity, and long-term patient adherence.

This study was conducted at the Khorezm Regional Multidisciplinary Medical Center and aimed to evaluate the safety and efficacy of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Patients were assessed based on virological, biochemical, and clinical parameters during extended antiviral therapy. The results demonstrate that long-term NA treatment effectively suppresses HBV replication, improves liver function, and is generally well tolerated, confirming the importance of continuous antiviral therapy in the management of chronic hepatitis B.

##submission.citations##

1. Anagul, S., & Shakhlo, Y. (2026). Modern approaches to early detection and therapy of hepatorenal syndrome. Frontiers of Knowledge and Interdisciplinary Discovery, 2(1), 326–335.

2. Buti M., Tsai N., Petersen J., et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457–1464.

3. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B. Hepatology. 2013;58(2):593–600.

4. Terrault N.A., Lok A.S.F., McMahon B.J., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B. Hepatology. 2018;67(4):1560–1599.

5. Papatheodoridis G.V., Chan H.L., Hansen B.E., Janssen H.L., Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with antiviral therapy. J Hepatol. 2015;62(4):956–967.

6. Yusupova, S. B., & Ikramov, M. D. (2026). Development of chronic kidney disease in non-alcoholic fatty liver disease. Frontiers of Knowledge and Interdisciplinary Discovery, 2(1), 382–389.

7. Yusupova, S. B., & Palvonova, G. U. (2026). Non-alcoholic fatty liver disease and chronic kidney disease: Physiological changes. Frontiers of Knowledge and Interdisciplinary Discovery, 2(1), 390–399.